Trial Profile
A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 17 Aug 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 22 May 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
- 10 Nov 2015 New trial record